FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study. [electronic resource]
Producer: 20160519Description: 162-9 p. digitalISSN:- 1938-0674
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Camptothecin -- adverse effects
- Cetuximab -- administration & dosage
- Colorectal Neoplasms -- drug therapy
- Disease-Free Survival
- Female
- Fluorouracil -- adverse effects
- Gene Expression Regulation, Neoplastic
- Humans
- Leucovorin -- adverse effects
- Male
- Middle Aged
- Mutation
- Neoplasm Metastasis
- PTEN Phosphohydrolase -- genetics
- Prognosis
- Prospective Studies
- Proto-Oncogene Proteins B-raf -- genetics
- Proto-Oncogene Proteins c-met -- genetics
- Proto-Oncogene Proteins p21(ras) -- genetics
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.